Pharmaceutical-Based Estrigenix Therapeutics Bags $2M in Seed Funding Round

The company will use the funding to advance lead optimization, complete its preclinical research, and prepare its lead programs for IND-enabling studies and future clinical trials.

The announcement follows several important milestones for the company, including securing an exclusive intellectual property license, appointing Victoria Zellmer as Chief Executive Officer, and making steady progress with its preclinical research. The company has also received interest from several pharmaceutical companies for potential partnerships around its lead drug candidate.

Read More:AI Startup Cascade Scores $3.5M in Funding Round

Unlike treatments that mainly relieve symptoms caused by lower estrogen levels, Estrigenix's selective non-steroid hormone ERβ platform is designed to target the underlying biology. This approach could support the development of new treatments for a range of women's health and neurodegenerative diseases.

Victoria Zellmer, Chief Executive Officer, Estrigenix Therapeutics: "This financing marks an important inflection point for Estrigenix. It reflects years of scientific progress and disciplined company building and it allows us to advance a differentiated platform toward clinical development while expanding the opportunities that platform can ultimately address."

Daniel Sem, Ph.D., J.D., Managing General Partner, Talents Fund: "Selective estrogen receptor-beta biology represents one of the most compelling opportunities in women’s health today. Estrigenix has assembled a differentiated platform with the potential to address multiple women’s health and neurodegenerative diseases through a common biological mechanism.

About Estrigenix Therapeutics

Founded in 2018, Estrigenix Therapeutics is a biotechnology company developing selective estrogen receptor-beta (ERβ) therapies for women's health and neurodegenerative diseases. The company's platform is designed to target ERβ to create new treatments for diseases with significant unmet medical needs.

Read More:Clean Tech Startup Sofab Inks Scores $6M in Seed Funding Round